Vaxart Reports Strong 2025 Financial Turnaround with $16.3M Net Income and Extended Cash Runway
Summary
Vaxart reported a significant financial improvement for full year 2025, achieving a net income of $16.3 million on substantially increased revenue, and extended its cash runway into Q2 2027 while advancing its vaccine pipeline.
Key Events
-
Achieved Net Income in 2025
Vaxart reported a net income of $16.3 million for the full year 2025, a significant improvement from a net loss of $66.9 million in 2024.
-
Substantial Revenue Growth
Revenue for the full year 2025 surged to $237.3 million, up from $28.7 million in 2024, primarily due to government contracts and the Dynavax collaboration.
-
Extended Cash Runway
The company ended 2025 with $63.8 million in cash, cash equivalents, and investments, providing a projected cash runway into the second quarter of 2027.
-
COVID-19 Trial Progress
Enrollment for the 5,400-participant Phase 2b COVID-19 trial is complete, with safety data from the sentinel cohort expected early Q2 2026 and topline data from all participants anticipated in Q4 2026.
Analysis
Vaxart's full year 2025 financial results demonstrate a significant turnaround, moving from a substantial net loss to profitability. The dramatic increase in revenue, primarily driven by government contracts and the Dynavax collaboration, coupled with an extended cash runway into Q2 2027, substantially de-risks the company's near-term operations. Progress in the pivotal Phase 2b COVID-19 trial and positive clinical data for the norovirus vaccine candidate further bolster the company's pipeline and strategic partnerships, indicating strong operational execution and potential for future growth.
At the time of this filing, VXRT was trading at $0.74 on OTC in the Life Sciences sector, with a market capitalization of approximately $176.9M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.